ALRN - Aileron Therapeutics, Inc. Trailing Twelve Months Revenue Growth

Brandmark of Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics (ALRN) delegates drug manufacturing and trials to external partners to maintain workforce mobility. The company is implementing automated molecule screening and software robots to analyze bone marrow protection data. Peptide platforms and the drug ALRN-6924 establish a foundation for long-term contracts with clinics. Year-over-year revenue change over the trailing twelve months (TTM) reflects demand dynamics, where 0.00 is the current value of the indicator.

Aileron Therapeutics, Inc. - ALRN Sales Growth YoY (TTM) (period 02/11/2024 - 11/18/2026)

Aileron Therapeutics - analytical breakdowns and key metrics (ALRN)

- price and consensus price forecast:
Fundamental company valuation:aileronrx.com ALRN
Flagship merchandise of Aileron

This indicator calculates the percentage change in the rolling sum of revenue over the last twelve months, allowing for the filtering of random market fluctuations to identify a sustainable operational trend. By analyzing the annual growth rate of sales volume on an LTM basis, an investor can observe the rebalancing effect of Aileron Therapeutics (ALRN) as it transitions toward orphan drug development, which transforms this chart into a tool for monitoring the shift in the business model.